Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune ...

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...

OSI Systems, NVE, Virpax Pharmaceuticals, Biodexa Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology ...

Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge.

Actuate Therapeutics' elraglusib shows promise for pancreatic cancer, but financial instability and risks make it a high-risk ...

A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...

suggesting an unreported paradigm for enzyme regulation. Glycogen phosphorylase kinase (PhK) initiates glycogen degradation by phosphorylating glycogen phosphorylase (GP), positioning itself at ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...